Article Text

Download PDFPDF
Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment
  1. D Mukherjee1,
  2. E J Topol2,
  3. D J Moliterno1,
  4. D M Brennan2,
  5. K Ziada1,
  6. L Cho3,
  7. S R Steinhubl1,
  8. for the CREDO Investigators
  1. 1Division of Cardiovascular Medicine and the Gill Heart Institute, Lexington, Kentucky, USA
  2. 2Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  3. 3Division of Cardiology, Loyola University Medical Center, Chicago, Illinois, USA
  1. Correspondence to:
    Dr Debabrata Mukherjee
    Gill Heart Institute, Division of Cardiovascular Medicine, University of Kentucky, 900 S Limestone Street, 326 Wethington Building, Lexington, Kentucky 40536-0200, USA; Mukherjee{at}


Objective: To assess the effectiveness of long term treatment with clopidogrel of patients with extracardiac vascular disease (ECVD) (a history of either peripheral arterial disease or cerebrovascular disease).

Design: Subgroup analysis of a prospective randomised clinical trial.

Setting: The CREDO (clopidogrel for the reduction of events during observation) trial was a randomised, double blind, placebo controlled trial conducted at 99 centres in North America from June 1999 through April 2001.

Patients: 2116 patients who were to undergo elective coronary intervention or were deemed at high likelihood of undergoing percutaneous coronary intervention were enrolled in the CREDO trial. The current study sample consisted of 272 patients with ECVD.

Main outcome measure: One year incidence of the composite of death, myocardial infarction, or stroke in the intent to treat population.

Results: Patients with ECVD had a more than twofold greater relative risk reduction with clopidogrel for the primary end point compared with patients without ECVD (47.9%, 95% confidence interval (CI) −4.2% to 73.9%, v 18.2%, 95% CI −10.5 % to 39.5%, respectively).

Conclusions: Longer term clopidogrel treatment provides added protection against thrombotic events throughout the arterial vasculature, not limited to the coronary arteries, and may be especially effective for patients with more diffuse atherosclerosis such as ECVD.

  • CI, confidence interval
  • CREDO, clopidogrel for the reduction of events during observation
  • ECVD, extracardiac vascular disease
  • PCI, percutaneous coronary intervention
  • peripheral arterial disease
  • clopidogrel
  • vascular disease
  • antiplatelet treatment

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 21 April 2005

Linked Articles